Connect with us

Fitness

Gene Variation Affects Success of Pain Drug in Women with Chronic Pain

Published

on

Gene Variation Affects Success of Pain Drug in Women with Chronic Pain


Register for free to listen to this article

Thank you. Listen to this article using the player above.


Want to listen to this article for FREE?


Complete the form below to unlock access to ALL audio articles.

In a study, women with chronic pelvic pain who had a naturally occurring variation of a gene, known as Neuregulin 3, in their DNA were more likely to experience relief after taking the painkilling drug gabapentin.

Targeting gabapentin use to those with this genetic marker would avoid ineffective treatment and unwanted side-effects in those who are unlikely to respond, experts say.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Persistent pain

The findings could improve use of gabapentin in treating chronic pelvic pain – a persistent, disabling pain which affects one in four women worldwide.

Gabapentin, often prescribed for chronic pain, targets the central nervous system – which carries messages between the brain and nerves throughout the body – to reduce heightened pain sensitivity that affects people with long-standing conditions.

The findings, from the University of Edinburgh, follow a previous study from the same team which suggested that gabapentin treatment was beneficial for certain women, with moderate improvements in the worst or average pelvic pain for 40 per cent of participants.

Genetic factor

The latest study, in collaboration with the University of Oxford, studied the genetic make-up of 71 women with chronic pelvic pain who received gabapentin – 29 responded to the medication and 42 saw no improvement.

They found a naturally occurring variation of the gene Neuregulin 3, which determined who would respond to gabapentin. The gene gives rise to a protein of the same name, found in the brain and spinal cord, which is involved in pain sensation and transmission.

The findings offer fresh insight into the underlying mechanisms behind chronic pain, and may have implications for other conditions besides pelvic pain, experts say.

A genetic factor that can predict how well gabapentin will work in patients offers the prospect of tailored treatment, and provides invaluable insights into understanding chronic pain. We hope eventually to use this genetic marker to optimise personalised treatment decisions and minimise adverse effects for women with chronic pelvic pain.

Dr Scott MackenzieLead author of the study, from the University’s Centre for Reproductive Health

Further research

The team say more research is needed to confirm the findings in a larger population of women. Their work is being supported by Edinburgh Innovations (EI), the University’s commercialisation service, which has patented the discovery and is seeking a commercial partner to further the research.

Isolating this single genetic marker is an important discovery that could ultimately help refine treatments for millions of women worldwide who suffer from chronic pelvic pain, as well as increasing our understanding of its role in other pain conditions. We believe this is an exciting opportunity for collaboration with a commercial partner who can help translate the research into a clinical setting.

Dr Susan BodieHead of Business Development for the College of Medicine and Veterinary Medicine at Edinburgh Innovations

The study is published in the journal iScience. It was funded by the EME programme – a partnership between the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) – and the Scottish Government’s Chief Scientist Office.

Reference: Mackenzie SC, Rahmioglu N, Romaniuk L, et al. Genome-wide association reveals a locus in neuregulin 3 associated with gabapentin efficacy in women with chronic pelvic pain. iScience. doi: 10.1016/j.isci.2024.110370

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

Continue Reading